Bart Clarke

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint New and emerging treatments for osteoporosis
    Bart L Clarke
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA
    Clin Endocrinol (Oxf) 71:309-21. 2009
  2. doi request reprint Coexisting primary hyperparathyroidism and sarcoidosis cause increased angiotensin-converting enzyme and decreased parathyroid hormone and phosphate levels
    Vivien Lim
    Mayo Clinic Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 98:1939-45. 2013
  3. doi request reprint Epidemiology of primary hyperparathyroidism
    Bart L Clarke
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    J Clin Densitom 16:8-13. 2013
  4. doi request reprint Corticosteroid-induced osteoporosis: an update for dermatologists
    Bart L Clarke
    Mayo Clinic School of Medicine, Rochester, MN, USA
    Am J Clin Dermatol 13:167-90. 2012
  5. pmc Female reproductive system and bone
    Bart L Clarke
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Arch Biochem Biophys 503:118-28. 2010
  6. pmc Physiology of bone loss
    Bart L Clarke
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA
    Radiol Clin North Am 48:483-95. 2010
  7. pmc Androgens and bone
    Bart L Clarke
    Mayo Clinic W18 A, 200 1st Street SW, Rochester, MN 55905, USA
    Steroids 74:296-305. 2009
  8. pmc Normal bone anatomy and physiology
    Bart Clarke
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, W18 A, 200 1st Street SW, Rochester, MN 55905, USA
    Clin J Am Soc Nephrol 3:S131-9. 2008
  9. doi request reprint Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys-Dietz syndrome
    Salman Kirmani
    Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Med Genet A 152:1016-9. 2010
  10. pmc Bisphosphonates: mechanism of action and role in clinical practice
    Matthew T Drake
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1032-45. 2008

Collaborators

Detail Information

Publications22

  1. doi request reprint New and emerging treatments for osteoporosis
    Bart L Clarke
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA
    Clin Endocrinol (Oxf) 71:309-21. 2009
    ..The increasing variety of new and emerging treatments increases the possibility that effective therapy will be targeted to the specific needs of the individual patient...
  2. doi request reprint Coexisting primary hyperparathyroidism and sarcoidosis cause increased angiotensin-converting enzyme and decreased parathyroid hormone and phosphate levels
    Vivien Lim
    Mayo Clinic Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 98:1939-45. 2013
    ..Primary hyperparathyroidism (PHPT) and sarcoidosis may separately contribute to abnormal calcium and phosphate metabolism via different mechanisms, and their coexistence is infrequently reported...
  3. doi request reprint Epidemiology of primary hyperparathyroidism
    Bart L Clarke
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    J Clin Densitom 16:8-13. 2013
    ..These limitations are due to the small number of population-based epidemiologic studies that have evaluated this condition. Further studies will be required to fully characterize the epidemiology of primary hyperparathyroidism...
  4. doi request reprint Corticosteroid-induced osteoporosis: an update for dermatologists
    Bart L Clarke
    Mayo Clinic School of Medicine, Rochester, MN, USA
    Am J Clin Dermatol 13:167-90. 2012
    ..This article gives an update of current knowledge regarding the pathophysiology, clinical presentation and evaluation, and prevention and treatment of patients with corticosteroid-induced osteoporosis...
  5. pmc Female reproductive system and bone
    Bart L Clarke
    College of Medicine, Mayo Clinic, Rochester, MN, USA
    Arch Biochem Biophys 503:118-28. 2010
    ....
  6. pmc Physiology of bone loss
    Bart L Clarke
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA
    Radiol Clin North Am 48:483-95. 2010
    ..Further elucidation of the relative importance of each of these factors will lead to improved preventive and therapeutic approaches for osteoporosis...
  7. pmc Androgens and bone
    Bart L Clarke
    Mayo Clinic W18 A, 200 1st Street SW, Rochester, MN 55905, USA
    Steroids 74:296-305. 2009
    ..Whether high doses of synthetic, non-aromatizable androgens may, in fact, be detrimental to bone due to suppression of endogenous testosterone (and estrogen) levels is a potential concern that warrants further study...
  8. pmc Normal bone anatomy and physiology
    Bart Clarke
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, W18 A, 200 1st Street SW, Rochester, MN 55905, USA
    Clin J Am Soc Nephrol 3:S131-9. 2008
    ..This information lays the groundwork for understanding the utility and clinical applications of iliac crest bone biopsy...
  9. doi request reprint Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys-Dietz syndrome
    Salman Kirmani
    Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Med Genet A 152:1016-9. 2010
    ..Osteopenia or osteoporosis may become increasingly important issues as earlier detection and treatment of the vascular complications of LDS improves life expectancy in these patients...
  10. pmc Bisphosphonates: mechanism of action and role in clinical practice
    Matthew T Drake
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 83:1032-45. 2008
    ....
  11. ncbi request reprint Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient
    Sreenivas Koka
    Metabolic Bone Disease Core Group, Division of Prosthodontics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Int J Prosthodont 20:115-22. 2007
    ..Within this context, management concepts and guidelines are presented to help the dental clinician allay concerns about BONJ expressed by patients receiving oral bisphosphonate therapy...
  12. ncbi request reprint Diagnosis, screening, prevention, and treatment of osteoporosis
    Karen F Mauck
    Division of General Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:662-72. 2006
    ..This article provides an overview of the diagnosis, screening, prevention, and treatment of osteoporosis...
  13. pmc Vitamin D insufficiency
    Tom D Thacher
    Department of Family Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:50-60. 2011
    ..Conclusive demonstration of these benefits awaits the outcome of controlled clinical trials...
  14. doi request reprint Bisphosphonates are not associated with vertebral osteonecrosis
    David F Kallmes
    Department of Radiology, Mayo Clinic, Rochester, MN, 55905, USA
    J Bone Miner Metab 27:452-5. 2009
    ..80). Intravertebral clefts are not associated with bisphosphonate therapy. If these clefts indicate osteonecrosis, then bisphosphonate therapy does not appear to be associated with vertebral osteonecrosis...
  15. pmc New selective estrogen and androgen receptor modulators
    Bart L Clarke
    Mayo Clinic W18 A, Rochester, Minnesota 55905, USA
    Curr Opin Rheumatol 21:374-9. 2009
    ..Both types of compounds hold great promise for therapeutic use in multiple hormonal disorders involving tissue-specific effects mediated by estrogen or androgen receptors...
  16. ncbi request reprint Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry
    Maureen M J Guichelaar
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 36:895-903. 2002
    ....
  17. ncbi request reprint Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease
    Maureen M J Guichelaar
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Bone Miner Res 18:2190-9. 2003
    ..Early post-transplant bone loss may be attributed to an additional insult to bone formation early after transplantation...
  18. ncbi request reprint Immunosuppressive and postoperative effects of orthotopic liver transplantation on bone metabolism
    Maureen M J Guichelaar
    Division of Liver Transplantation, Mayo Clinic, Rochester, MN 55905, USA
    Liver Transpl 10:638-47. 2004
    ..Other factors important in the recovery of bone metabolism after the early phase of bone loss are recovery of liver and gonadal function and better calcium balance...
  19. ncbi request reprint Glucocorticoid-induced osteoporosis in dermatologic practice: a review
    Yulia K Khan
    Mayo Medical School, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Drugs Dermatol 7:1053-9. 2008
    ..This summary should aid dermatologists in providing education and recommendations regarding bone health for their patients on systemic glucocorticoids...
  20. ncbi request reprint Site specificity of regular health club exercise on muscle strength, fitness, and bone density in women aged 29 to 45 years
    Mehrsheed Sinaki
    Department of Physical Medicine and Rehabilitation, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:639-44. 2004
    ..To determine the effect of regular exercise with use of stepper or skier machines on muscle strength, cardiovascular fitness, bone mineral density, and markers of bone turnover in women aged 29 to 45 years...
  21. ncbi request reprint Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism
    Peter J Tebben
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:1508-13. 2004
    ..To determine whether fibroblast growth factor 23 (FGF23) contributes to the hypophosphatemia of primary hyperparathyroldism...
  22. ncbi request reprint Long-term fracture risk following renal transplantation: a population-based study
    Line M Vautour
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minn, USA
    Osteoporos Int 15:160-7. 2004
    ..Diabetic patients, particularly, experience excess lower limb fractures. Patients and their care providers should be aware of this elevated fracture risk, which continues long-term...